Currently, there are 116.36M common shares owned by the public and among those 87.26M shares have been available to trade.
The company’s stock has a 5-day price change of -9.09% and -85.99% over the past three months. APLT shares are trading -67.16% year to date (YTD), with the 12-month market performance down to -62.84% lower. It has a 12-month low price of $1.03 and touched a high of $10.62 over the same period. APLT has an average intraday trading volume of 5.70 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -73.58%, -84.42%, and -81.43% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Applied Therapeutics Inc (NASDAQ: APLT) shares accounts for 88.02% of the company’s 116.36M shares outstanding.
It has a market capitalization of $127.99M and a beta (3y monthly) value of 1.73. The earnings-per-share (ttm) stands at -$1.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.79% over the week and 12.81% over the month.
Earnings per share for the fiscal year are expected to increase by 1.41%, and 56.22% over the next financial year.
Looking at the support for the APLT, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on December 02, 2024, with the firm’s price target at $13-$2. RBC Capital Mkts coverage for the Applied Therapeutics Inc (APLT) stock in a research note released on November 29, 2024 offered a Sector Perform rating with a price target of $4. William Blair was of a view on July 31, 2024 that the stock is Outperform, while RBC Capital Mkts gave the stock Outperform rating on March 26, 2024, issuing a price target of $12. Leerink Partners on their part issued Outperform rating on February 22, 2024.
